ARTICLE | Clinical News

Remicade infliximab: Phase III data

May 16, 2011 7:00 AM UTC

Patients who achieved a clinical response at week 8 were randomized to receive 5 mg/kg Remicade every 8 weeks through week 46 (n=22) or every 12 weeks through week 42 (n=23). At week 54, a non-significantly greater proportion of patients receiving Remicade every 8 weeks were in clinical remission vs. Remicade every 12 weeks (38.1% vs. 18.2%, p=0.146). J&J said the result did not reach statistical significance due to the small sample sizes. Additionally, 38.5% of patients receiving Remicade every 8 weeks who were also receiving corticosteroids at baseline were in clinical remission and off corticosteroids at week 54 vs. 0% of patients in the every 12-week Remicade maintenance group. Data were presented at the Digestive Disease Week meeting in Chicago. ...